Tehran University of Medical Sciences

Science Communicator Platform

Share By
The Effect of Alpha Lipoic Acid Supplementation on Inflammatory Markers, Lipoprotein Lipase and Metabolic Profile in Patients With Psoriasis: A Randomized Clinical Trial Publisher



Nouri A ; Mostafazadeh P ; Javadi F ; Azizpour A ; Hajiabbasoghli S ; Hoseinzadeh MJ ; Ebrahimpourkoujan S
Authors

Source: Archives of Dermatological Research Published:2026


Abstract

Psoriasis, a chronic inflammatory disease, is associated with metabolic disturbances and oxidative stress. Alpha-lipoic acid (ALA), a potent antioxidant with anti-inflammatory properties, may offer therapeutic benefits, but its effects in psoriasis remain unexplored. This randomized, double-blind, placebo-controlled trial enrolled 40 patients with psoriasis (20 per group) aged 20–60 years. Participants were randomized to receive either 600 mg/day ALA or a placebo for 8 weeks. Serum inflammatory markers (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lipoprotein lipase (LPL), malondialdehyde (MDA), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)), and lipid profiles were measured at baseline and after intervention. Data were analyzed using intention-to-treat analysis with repeated measures ANOVA and ANCOVA adjusted for baseline values, sun exposure, and dietary fat. ALA supplementation was associated with significant reductions in CRP (adjusted p = 0.026) and LPL (adjusted p = 0.005). In contrast, it did not produce any significant changes in lipid profiles or in oxidative stress status as reflected by MDA. Similarly, ESR and liver enzymes showed no significant alterations. Adherence was greater than 80% with no adverse events reported. ALA supplementation for 8 weeks improved inflammatory markers (CRP, LPL) in psoriatic patients but did not affect lipid profiles or oxidative stress. The observed liver enzyme changes appeared confounded by baseline characteristics. These modest reductions in CRP and LPL may reflect improvements in systemic inflammation and lipid metabolism, which are clinically relevant given the increased cardiometabolic risk in patients with psoriasis. Trial Registration: Iranian Registry of Clinical Trials, IRCT20230123057193N3 was registered on 2024.03.29. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2026.
Other Related Docs
5. Metabolomics Analysis of Serum Fatty Acids in Patients With Psoriasis, Archives of Dermatological Research (2025)